Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign-up to receive all GMG announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Optimizing Antimicrobial Stewardship Program in Saudi Arabia
    Release Date:
    Review Process: Expert Review Panel
    Quality Improvement Inflammation & Immunology Saudi Arabia
    Shared Decision Making in Hemophilia Patient Care
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Rare Disease USA
    Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
    Release Date:
    Review Process: Pfizer Internal
    Research Oncology All
    Pharmacokinetics-pharmacodynamics (PK-PD) of aztreonam-avibactam (ATM-AVI) in Special Populations
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology Austria, Denmark, Finland, Germany, Italy, Netherlands, Norway, Romania, Spain, Sweden, United Kingdom
    Invasive Mold Infections (IMI) - Real-World Evidence from Treatment Outcomes with Isavuconazole
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology Australia, Germany, Israel, Italy, Spain, Switzerland
    Optimizing maternal immunization practice in Malaysia Indonesia Singapore Philippines
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Vaccines Indonesia, Malaysia, Philippines, Singapore
    PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Pediatric pneumococcal carriage and serotype distribution surveillance: prospective studies in South-East Asia, 2025-2026
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines India, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, Vietnam
    Advancing Health Care Professionals’ knowledge and understanding of adult and maternal vaccination against respiratory infection
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Finland, Greece, Hungary, Ireland, Israel, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia (Slovak Republic), Slovenia, Ukraine
    Review and analysis of serotype distribution and burden of pneumococcal disease in children younger than 5 years – Post vac era
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines Burkina Faso, Congo, The Democratic Republic, Cote D'ivoire, Ethiopia, Ghana, Mozambique, Pakistan, Senegal, Sudan, Tanzania, United Republic of
    The Clinical Application of ATM-AVI in Patients with CRE Infections, including MBL-Producing CRE
    Release Date:
    Review Process: Pfizer Internal
    Research Hospital China, Hong Kong
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    NSCLC Biomarker Testing
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology Andorra, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Liechtenstein, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Spain, Sweden, Switzerland, USA, United Kingdom
    Development of Talazoparib for Prostate Cancer
    Release Date:
    Partner: National Comprehensive Cancer Network
    Review Process: Expert Review Panel
    Research Oncology USA
    Approaches to Smoking Cessation Counseling
    Release Date:
    Review Process: Pfizer Internal
    Education Internal Medicine Australia, India, Japan, New Zealand, Singapore, Taiwan
    Burden of Community Acquired Pneumonia
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines USA
    Closing Knowledge Gaps in Moderate-to-Severe Alopecia Areata
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    Progress in Androgen Deprivation Therapy (ADT) in Advanced Prostate Cancer
    Release Date:
    Partner: Myovant Sciences
    Review Process: Pfizer Internal
    Education Oncology USA
    Efforts to Promote Team-based Care and Regional Medical Collaboration for Cancer Patients
    Release Date:
    Partner: Japan Society of Clinical Oncology
    Review Process: Expert Review Panel
    Quality Improvement Oncology Japan
    ISID-Pfizer 2021 Grant Challenge
    Release Date:
    Partner: The International Society for Infectious Diseases (ISID)
    Review Process: Expert Review Panel
    Quality Improvement Hospital All
    China Medical Education in Breast Cancer Diagnosis and Treatment
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology China
    Hemophilia: Improve Knowledge Level of Gene Therapy
    Release Date:
    Review Process: Pfizer Internal
    Education Rare Disease Japan
    Data generation on the treatment of Metastatic Breast Cancer with CDK 4/6 inhibitors
    Release Date:
    Review Process: Expert Review Panel
    Research Oncology Portugal
    COVID-19 Epidemiology Research
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines Algeria, Egypt, Indonesia, Lebanon, Philippines, Thailand, Tunisia, Vietnam